Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development.

Huh SJ, Liang S, Sharma A, Dong C, Robertson GP.

Cancer Res. 2010 Jul 15;70(14):6071-82. doi: 10.1158/0008-5472.CAN-09-4442. Epub 2010 Jul 7.

2.

Update on melanoma: the present position.

Godden D, Brennan PA, Milne J.

Br J Oral Maxillofac Surg. 2010 Dec;48(8):575-8. doi: 10.1016/j.bjoms.2009.10.029. Epub 2009 Dec 16. Review.

PMID:
20015580
3.

Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP.

Clin Cancer Res. 2009 Mar 1;15(5):1674-85. doi: 10.1158/1078-0432.CCR-08-2214. Epub 2009 Feb 10.

4.

Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Allen NE, Appleby PN, Roddam AW, Tjønneland A, Johnsen NF, Overvad K, Boeing H, Weikert S, Kaaks R, Linseisen J, Trichopoulou A, Misirli G, Trichopoulos D, Sacerdote C, Grioni S, Palli D, Tumino R, Bueno-de-Mesquita HB, Kiemeney LA, Barricarte A, Larrañaga N, Sánchez MJ, Agudo A, Tormo MJ, Rodriguez L, Stattin P, Hallmans G, Bingham S, Khaw KT, Slimani N, Rinaldi S, Boffetta P, Riboli E, Key TJ; European Prospective Investigation into Cancer and Nutrition.

Am J Clin Nutr. 2008 Dec;88(6):1567-75. doi: 10.3945/ajcn.2008.26205.

5.

Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates.

Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S.

J Med Chem. 2008 Dec 25;51(24):7820-6. doi: 10.1021/jm800993r.

6.

A novel AKT3 mutation in melanoma tumours and cell lines.

Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB.

Br J Cancer. 2008 Oct 21;99(8):1265-8. doi: 10.1038/sj.bjc.6604637. Epub 2008 Sep 23.

7.

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP.

Cancer Res. 2008 Sep 15;68(18):7638-49. doi: 10.1158/0008-5472.CAN-07-6614.

8.

Malignant melanoma in the 21st century: the emerging molecular landscape.

Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN; Melanoma Study Group of Mayo Clinic Cancer Center.

Mayo Clin Proc. 2008 Jul;83(7):825-46. Review.

9.

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP.

Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.

10.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.

J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288.

PMID:
18445842
11.

Emerging therapies for melanoma.

Katipamula R, Markovic SN.

Expert Rev Anticancer Ther. 2008 Apr;8(4):553-60. doi: 10.1586/14737140.8.4.553. Review.

PMID:
18402522
12.

Selenium compounds and selenoproteins in cancer.

Brigelius-Flohé R.

Chem Biodivers. 2008 Mar;5(3):389-95. doi: 10.1002/cbdv.200890039. Review.

PMID:
18357548
13.

The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?

Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A.

J Invest Dermatol. 2008 Apr;128(4):957-71. Epub 2007 Oct 18.

14.

PRAS40 deregulates apoptosis in malignant melanoma.

Madhunapantula SV, Sharma A, Robertson GP.

Cancer Res. 2007 Apr 15;67(8):3626-36.

15.

Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis.

Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET; Melanoma Study Group of the Mayo Clinic Cancer Center.

Mayo Clin Proc. 2007 Mar;82(3):364-80. Review.

PMID:
17352373
16.

Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.

Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Griendling K, Martínez-Diez M, Cuezva JM, Arbiser JL.

J Clin Invest. 2007 Mar;117(3):719-29. Epub 2007 Feb 22.

17.
18.

Progress and prospects on melanoma: the way forward for early detection and reduced mortality.

Weinstock MA.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2297s-2300s. Review.

19.

Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds.

El-Bayoumy K, Sinha R, Pinto JT, Rivlin RS.

J Nutr. 2006 Mar;136(3 Suppl):864S-869S. Review.

20.

Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action.

Zhang Y, Yao S, Li J.

Proc Nutr Soc. 2006 Feb;65(1):68-75. Review.

PMID:
16441946

Supplemental Content

Support Center